In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lay Line Genomics SPA

www.laylinegenomics.com

Latest From Lay Line Genomics SPA

Glenmark enters clinic with 'derisked' early stage pain MAb

Glenmark Pharmaceuticals is moving ahead in the UK with the development of GBR-900, its "derisked" first in class monoclonal antibody for chronic pain targeting tyrosine kinase A (TrkA), the receptor of nerve growth factor (NGF).

Gastrointestinal Cancer

INTERVIEW: Glenmark on the promise of emerging markets and niche US generics

Glenmark's chairman and managing director, Glenn Saldanha, believes that key emerging markets now caught up in a vortex of regulatory change will deliver their promise in the long run, although the short term could be fraught with pain.

Orthopedics Neurology

Sanofi licenses novel monoclonal from Glenmark for up to $663 million

In a significant move that may switch the image of India in biologics from a follower to a leader, Glenmark Pharmaceuticals has granted French drugs giant Sanofi a licence for the development and commercialisation of a novel monoclonal antibody for the treatment of Crohn's disease and other chronic autoimmune conditions. The deal involves a $50 million up front payment to Glenmark.

Gastrointestinal Dermatology

Anti-CD19 antibody rivalry intensifies as Glenmark unveils new candidate

Glenmark Pharmaceuticals is developing an anti-CD19 monoclonal antibody for the potential treatment of B-cell malignancies such as non-Hodgkin's lymphoma (NHL).

Gastrointestinal Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • Lay Line Genomics SPA
  • Senior Management
  • Ennio Esposito, Dir.
  • Contact Info
  • Lay Line Genomics SPA
    Phone: (39) 06-65746169
    Viale Prospero Colonna 32, c/o Studio
    Miglionico
    Rome, 00149
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register